169 related articles for article (PubMed ID: 37861217)
41. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Libman IM; Miller KM; DiMeglio LA; Bethin KE; Katz ML; Shah A; Simmons JH; Haller MJ; Raman S; Tamborlane WV; Coffey JK; Saenz AM; Beck RW; Nadeau KJ;
JAMA; 2015 Dec; 314(21):2241-50. PubMed ID: 26624824
[TBL] [Abstract][Full Text] [Related]
42. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Pescovitz MD; Greenbaum CJ; Krause-Steinrauf H; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; McGee PF; Moran AM; Raskin P; Rodriguez H; Schatz DA; Wherrett D; Wilson DM; Lachin JM; Skyler JS;
N Engl J Med; 2009 Nov; 361(22):2143-52. PubMed ID: 19940299
[TBL] [Abstract][Full Text] [Related]
43. Anti-CD3 clinical trials in type 1 diabetes mellitus.
Daifotis AG; Koenig S; Chatenoud L; Herold KC
Clin Immunol; 2013 Dec; 149(3):268-78. PubMed ID: 23726024
[TBL] [Abstract][Full Text] [Related]
44. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
[TBL] [Abstract][Full Text] [Related]
45. INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes.
Pedersen IB; Kjolby M; Hjelholt AJ; Madsen M; Christensen AR; Adolfsen D; Hjelle JS; Kremke B; Støvring H; Jessen N; Vestergaard ET; Kristensen K; Frobert O
BMJ Open; 2024 Jul; 14(6):e084808. PubMed ID: 38950997
[TBL] [Abstract][Full Text] [Related]
46. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
47. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.
Mastrandrea L; Yu J; Behrens T; Buchlis J; Albini C; Fourtner S; Quattrin T
Diabetes Care; 2009 Jul; 32(7):1244-9. PubMed ID: 19366957
[TBL] [Abstract][Full Text] [Related]
48. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
Arslanian SA; Hannon T; Zeitler P; Chao LC; Boucher-Berry C; Barrientos-Pérez M; Bismuth E; Dib S; Cho JI; Cox D;
N Engl J Med; 2022 Aug; 387(5):433-443. PubMed ID: 35658022
[TBL] [Abstract][Full Text] [Related]
49. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.
Waldron-Lynch F; Henegariu O; Deng S; Preston-Hurlburt P; Tooley J; Flavell R; Herold KC
Sci Transl Med; 2012 Jan; 4(118):118ra12. PubMed ID: 22277969
[TBL] [Abstract][Full Text] [Related]
50. Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes.
Gaglia JL; Daley HL; Bryant NK; Ritz J; Dong T; Skyler JS; Jiang H
NEJM Evid; 2024 Jul; 3(7):EVIDoa2300238. PubMed ID: 38916421
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression.
Ashraf MT; Ahmed Rizvi SH; Kashif MAB; Shakeel Khan MK; Ahmed SH; Asghar MS
Diabetes Obes Metab; 2023 Nov; 25(11):3377-3389. PubMed ID: 37580969
[TBL] [Abstract][Full Text] [Related]
52. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
53. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.
Foley JE; Bunck MC; Möller-Goede DL; Poelma M; Nijpels G; Eekhoff EM; Schweizer A; Heine RJ; Diamant M
Diabetologia; 2011 Aug; 54(8):1985-91. PubMed ID: 21547496
[TBL] [Abstract][Full Text] [Related]
54. Teplizumab therapy for type 1 diabetes.
Masharani UB; Becker J
Expert Opin Biol Ther; 2010 Mar; 10(3):459-65. PubMed ID: 20095914
[TBL] [Abstract][Full Text] [Related]
55. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.
Griffin KJ; Thompson PA; Gottschalk M; Kyllo JH; Rabinovitch A
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):710-8. PubMed ID: 24997559
[TBL] [Abstract][Full Text] [Related]
56. Teplizumab: First Approval.
Keam SJ
Drugs; 2023 Apr; 83(5):439-445. PubMed ID: 36877454
[TBL] [Abstract][Full Text] [Related]
57. Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.
Pinckney A; Rigby MR; Keyes-Elstein L; Soppe CL; Nepom GT; Ehlers MR
Clin Ther; 2016 Jun; 38(6):1327-1339. PubMed ID: 27209482
[TBL] [Abstract][Full Text] [Related]
58. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
Haller MJ; Gitelman SE; Gottlieb PA; Michels AW; Rosenthal SM; Shuster JJ; Zou B; Brusko TM; Hulme MA; Wasserfall CH; Mathews CE; Atkinson MA; Schatz DA
J Clin Invest; 2015 Jan; 125(1):448-55. PubMed ID: 25500887
[TBL] [Abstract][Full Text] [Related]
59. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
Couri CE; Oliveira MC; Stracieri AB; Moraes DA; Pieroni F; Barros GM; Madeira MI; Malmegrim KC; Foss-Freitas MC; Simões BP; Martinez EZ; Foss MC; Burt RK; Voltarelli JC
JAMA; 2009 Apr; 301(15):1573-9. PubMed ID: 19366777
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
